The RET proto-oncogene: a molecular therapeutic target in thyroid cancer (Q36072495)

12 August 2017

1 reference

title

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer (English)

1 reference

12 August 2017

Yoshinori Kodama

1

1 reference

12 August 2017

Naoya Asai

2

1 reference

12 August 2017

Kumi Kawai

3

1 reference

12 August 2017

Mayumi Jijiwa

4

1 reference

12 August 2017

Yoshiki Murakumo

5

1 reference

12 August 2017

Masatoshi Ichihara

6

1 reference

12 August 2017

Masahide Takahashi

7

1 reference

12 August 2017

publication date

1 March 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

96

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

143-148

1 reference

Activation of a novel human transforming gene, ret, by DNA rearrangement

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

ret transforming gene encodes a fusion protein homologous to tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Characterization of a multicomponent receptor for GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The GDNF family: signalling, biological functions and therapeutic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Renal and neuronal abnormalities in mice lacking GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Defects in enteric innervation and kidney development in mice lacking GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Renal agenesis and the absence of enteric neurons in mice lacking GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The GDNF/RET signaling pathway and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The RET proto-oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

RET and NTRK1 proto-oncogenes in human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The RET proto-oncogene: a potential target for molecular cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

RET and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The Ret Receptor Protein Tyrosine Kinase Associates with the SH2-containing Adapter Protein Grb10

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Role of Dok1 in cell signaling mediated by RET tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

MEN2A-RET-induced cellular transformation by activation of STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Antiproliferative effects of Src inhibition on medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00023.X

10.1111/J.1349-7006.2005.00023.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference